| ²é¿´: 3378 | »Ø¸´: 13 | |||
[½»Á÷]
ÇóÖúÈçºÎ²éµ½ÍùÄêÖбêµÄ»ù½ðÉêÇëÊéÕªÒª
|
| ±¾È˵ÚÒ»´ÎдÇàÄê»ù½ð£¬Éí±ßûÓÐÈË׫д£¬Ïë²Î¿¼Ò»Ï±ðÈ˵İ汾£¬ÔÚ¹ú»ùÍøÉÏÖ»Äܲ鵽ÏîÄ¿Ãû³ÆºÍ±àºÅ£¬ÄÄλ¸ßÈ˴ͽ̣ºµ½ÄÄ¿ÉÒԲ鵽ÒÑÖÐÏîÄ¿µÄÕªÒª£¿Ð»Ð» |
» ²ÂÄãϲ»¶
¹ú¼Ò»ù½ðÉêÇëÊéÄ£°åÄÚ²åÈëͼƬ²»¿Éµ÷Õû´óС?
ÒѾÓÐ9È˻ظ´
ÍËѧ»ò¼á³Ö¶Á
ÒѾÓÐ20È˻ظ´
ÃâÒßѧ²©Ê¿ÓÐÃû¶î£¬ËÙÁªÏµ
ÒѾÓÐ14È˻ظ´
ÃæÉÏ»ù½ðÉ걨ûÓÐÆäËûµÄ²ÎÓëÕß³ÉÂð
ÒѾÓÐ4È˻ظ´
¶à×é·Ö¾«ÁóÇóÖú
ÒѾÓÐ6È˻ظ´
¹ú¼Ò¼¶È˲ſÎÌâ×éÕÐÊÕ2026ÄêÈëѧ²©Ê¿
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÈçºÎÄܲ鵽¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÉêÇëÊéµÄÕªÒª£¿
ÒѾÓÐ5È˻ظ´
Ôõô¸øÉêÇëÊéÆðÃû×Ö£¬ÇóÖú°¡
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿Çó½ðÊô¸¯Ê´Óë·À»¤·½ÃæµÄÍùÄê¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÉêÇëÊé
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿¼±ÇóÖбêÐÂÊÀ¼ÍÓÅÐãÈ˲ÅÖ§³Ö¼Æ»®ÉêÇëÊé
ÒѾÓÐ11È˻ظ´
²ËÄñÇóÖú£¬¼ª°²ºóºÓµ÷²éÉêÇëÊéÖÐÁ¢ÏîÒÀ¾ÝºÍ¿ÉÐÐÐÔ·ÖÎöÈçºÎд£¿
ÒѾÓÐ19È˻ظ´
ÈçºÎ²éѯÍùÄêÖбêµÄ×ÔÈ»»ù½ðµÄÌâÄ¿ºÍÕªÒªµÈÐÅÏ¢£¿
ÒѾÓÐ3È˻ظ´
ÇóÖú£ºÇëÎʹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðµÄ½á¹û´ÓÄÄÀï¿ÉÒԲ鵽£¿·Ç³£¸Ðл£¡
ÒѾÓÐ6È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÄÏ·½Ò½¿Æ´óѧÖÐҩѧԺ ÉêÇ뿼ºË²©Ê¿Ò»Ãû £¨ÌìȻҩ»¯·½Ïò£¬ÌìÈ»²úÎï·ÖÀë¾ÑéÓÅÏÈ£©
+1/274
Ïã¸ÛÁëÄÏ´óѧ¹ùçø¿ÎÌâ×鲩ʿÕÐÉú (2026ÄêÇï¼¾Èëѧ£©
+1/186
Postdoctoral Research Fellow Position in Causal Inference Weill CorneIl Medicine
+1/92
Ìì½ò¿Æ¼¼´óѧµËÆôÁ¼½ÌÊÚÍÅ¶Ó ÕÐÊÕ2026Ä격ʿÉú
+1/80
Öйúº£Ñó´óѧÓëÖйúË®²ú¿ÆÑ§Ñо¿Ôº ÁªºÏÅàÑø ר˶ ʳƷ¼Ó¹¤Ó밲ȫ
+1/77
ÃÀ¹úR1´óѧ--µÂ¿ËÈøË¹´óѧ°£¶ûÅÁË÷·ÖУ£¨UTEP£© ÍÁľ¡¢»·¾³Ó뽨Öþ¹¤³Ìϵ ²©Ê¿ÕÐÉú
+1/76
·ÇÁ¸ÉúÎïÖÊÄܼ¼ÊõÈ«¹úÖØµãʵÑéÊҺϳÉÉúÎïѧ´´ÐÂÍŶÓÈ«ÇòÕÐÆ¸²©Ê¿/²©Ê¿ºó
+1/74
ÍÞÍÞÃǽñ¶ù¿¼ÊÔà¶¡£¡£¡£¡£
+1/63
Ïã¸Û¿Æ¼¼´óѧ¼ÆËãÎïÀí¼°Á÷ÌåÁ¦Ñ§¿ÎÌâ×éÕÐÊÕÈ«½±²©Ê¿ºó¼°²©Ê¿Éú£¨2026Äê9ÔÂÈëѧ£©
+1/36
ÄÏ·½Ò½¿Æ´óѧÉúÎïҽѧ¹¤³ÌѧԺÕÐÊÕÉêÇ뿼ºËÖÆ²©Ê¿Éú2Ãû¡¢²©Ê¿ºó2Ãû£¨2026£©
+1/31
ɽ¶«¿Æ¼¼´óѧÕÐÆ¸»¯Ñ§»¯¹¤²©Ê¿²©Ê¿ºó
+1/28
½Î÷Àí¹¤´óѧ Ï¡ÍÁѧԺ Ï¡ÍÁ¹¦ÄܲÄÁÏ·½Ïò ÕÐÊÕ2026½ì²©Ê¿Ñо¿Éú¡¢Ë¶Ê¿Ñо¿Éú
+1/28
ÁªºÏÑо¿ÍŶÓÕÐÆ¸²©ºóµÈÇàÄêÈ˲Å
+1/9
ÉϺ£Àí¹¤´óѧ¹ËÃôԺʿ¡¢ÕÅéó骽ÌÊÚÍÅ¶Ó ÕÐÆ¸ 2026¼¶ ¹âѧ¹¤³Ì ²©Ê¿Éú
+1/7
°Ä¿Æ´óÕÐÊÕ2026ÄêÇï¼¾Èëѧҩ¼Áѧ/ÉúÎï²ÄÁÏ·½ÏòÈ«½±²©Ê¿Ñо¿Éú
+1/7
ɽ¶«´óѧ¼¯³Éµç·ѧԺÍõÁèÔÆÑо¿Ô±ÕÐÊÕ2026Äê˶ʿÉú¼°ÁªºÏÅàÑøË¶Ê¿Éú
+1/3
»ªÄÏÀí¹¤´óѧË⨽ÌÊÚÁªºÏÌÆ±¾ÖÒԺʿÕÐÆ¸»¯Ñ§ºÍ²ÄÁÏ·½Ïò²©Ê¿ºó£¨³¤ÆÚÓÐЧ£©
+1/3
Î人¹¤³Ì´óѧ¶Ö¾±ø½ÌÊÚ¿ÎÌâ×éÕÐÊÕ²©Ê¿/˶ʿÑо¿Éú£¨³¤ÆÚÓÐЧ£©
+1/2
°Ä¿Æ´ó³ÏÕÐ2026ÄêÇï¼¾ÉúÎï²ÄÁÏÈ«½±²©Ê¿Ñо¿Éú£¨½ñÈÕ16:30ÏßÉÏÐû½²»á£©
+1/1
¹ãÖÝÒ½¿Æ´óѧ Íõ¾² ˯ÃßÓëÉñ¾¾«Éñ¼²²¡¿ÎÌâ×é ²©Ê¿ºó¡¢Ë¶Ê¿Ñо¿Éú¡¢Ñо¿ÖúÀí¡¢¼ûϰÉúÕ
+1/1
2Â¥2011-02-20 12:49:24
¡ï
yunew80(½ð±Ò+1):лл²ÎÓë
yunew80(½ð±Ò+1): ºÜºÃ 2011-02-22 09:26:20
yunew80(½ð±Ò+1):лл²ÎÓë
yunew80(½ð±Ò+1): ºÜºÃ 2011-02-22 09:26:20
|
07ÄêÒÔǰµÄ¿ÉÒÔ´Ó»ù½ðί¾ÉÍøÕ¾²éÕªÒª¡£ |
3Â¥2011-02-20 13:38:08
4Â¥2011-02-20 14:28:10
|
http://npd.nsfc.gov.cn/ResearchNet_NSFC/index.aspx µã»÷-->ÉúÃü¿ÆÑ§²¿£¬ µã»÷-->×ÊÖúÏîÄ¿£¬ µã»÷-->±êÌ⣬ ×îºóµã»÷-->ÏîĿժҪ¡£ |
5Â¥2011-02-20 20:30:27
koushuiji88
Ìú¸Ëľ³æ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ½ð±Ò: 10028.8
- Ìû×Ó: 10398
- ÔÚÏß: 696.2Сʱ
- ³æºÅ: 976193
6Â¥2011-02-20 20:42:34
7Â¥2011-02-20 20:45:06
stoutgun
ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 10 (Ó×¶ùÔ°)
- ¹ó±ö: 0.05
- ½ð±Ò: 21719.1
- Ìû×Ó: 10363
- ÔÚÏß: 1313Сʱ
- ³æºÅ: 609491
¡ï
yunew80(½ð±Ò+1):лл²ÎÓë
yunew80(½ð±Ò+1):лл²ÎÓë
|
»ù½ðίû¹ØÏµµÄ»°Ã»°ì·¨²éµÄ¡£ ²»¹ýÄã¿ÉÒÔËÑË÷Ò»ÏÂСľ³æ£¬ÒÔǰÓÐºÜ¶à³æ×ÓÌù¹ýµÄ |
8Â¥2011-02-20 20:47:46
|
¸ÕÊÔÓùý£¬ÀýÈ磺 Ãû³Æ£º¹²±í´ïRSVÖкͿ¹ÔµÄDNAºÍ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÖØ×éÌåµÄ¹¹½¨¼°Æä±£»¤×÷Óà ------------------------------------------------------- ÖÐÎÄÕªÒª£º RSVÊǵ¼ÖÂÓ¤Ó×¶ùÑÏÖØÏºôÎüµÀ¸ÐȾµÄ×îÖØÒªµÄ²¡¶¾²¡Ô£¬Í¬Ê±Ò²ÊÇÒýÆðÀÏÈË·¢²¡ºÍËÀÍöµÄÖØÒªÔÒò¡£²¡¶¾¸ÐȾ»úÌåºóµÄÃâÒß±£»¤»úÖÆÉÐδÃ÷È·£¬Ò²ÎÞÌØÒìÐÔ·ÀÖη½·¨¡£ÒÔÕæºË±í´ïÖÊÁ£ºÍ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÎªÔØÌå¹²±í´ïRSVÁ½ÖÖÖкͿ¹ÔFºÍG£¬²¢Ñо¿ÆäÃâÒß±£»¤×÷ÓÃÊÇ̽Ë÷RSVÒßÃçµÄÓÐÒæ³¢ÊÔ¡£Ä¿Ç°£¬ÒѾÍê³ÉÑо¿¼Æ»®ÖеÄÒ»Ð©ÖØÒªÄÚÈÝ£¬ÈçÁ½ÖÖRSVÖкͿ¹Ô±àÂë»ùÒòµÄ¿Ë¡£¬ÖØ×éÏÙ²¡¶¾¼ò±ã¸ßЧµÄ¸Ä½¨·½·¨£¬¿É½øÐй²±í´ïµÄÏÙ²¡¶¾ÔØÌåϵͳµÄ¹¹½¨£¬·Ö±ð±í´ïFºÍGµ°°×µÄ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÖØ×éÌåµÄ¹¹½¨ºÍ¼ø¶¨¹¤×÷µÈ¡£ÒÑÅàÑøË¶Ê¿Ñо¿Éú3Ãû£¬·¢±íÂÛÎÄ4ƪ£¬ÆäÖкËÐÄÆÚ¿¯3ƪ¡£ÕâЩ¹¤×÷Ϊ¼ÌÐøÍê³ÉÓàϵĿÎÌâÈÎÎñµì¶¨ÁË»ù´¡¡£ ÖÐÎÄÖ÷Ìâ´Ê£º ºôÎüµÀºÏ°û²¡¶¾£»ÏÙ²¡¶¾ÖØ×éÌ壻ÃâÒß±£»¤×÷Óã»ÖкͿ¹Ô£»¹²±í´ï Ó¢ÎÄÕªÒª: Human respiratory syncytial virus (RSV) is the most important viral etiologic agent of pediatric lower respiratory tract disease worldwide. RSV disease is also responsible for considerable morbidity and mortality in the elderly. The mechanisms that contribute to the disease protection are not fully understood. Currently no safe and efficacious RSV vaccine is available. It will be helpful for the RSV vaccine program to investigate their expression and protective immunity of DNA and replication-defective adenoviral recombinants encoding the attachment (G) and fusion (F) protein. Till now, we have finished the clone and eukaryotic expression of F and G gene of subgroup A Long strain RSV, established a more effective and easier method for constructing recombinant adenovirus based on AdEasy System, constructed replication deficient adenovirus vector system used as expressing F and G protein simultaneously and the adenoviral recombinants expressing the F and G protein, respectively. All these achievements provide a good basis for further study. Ó¢ÎÄÖ÷Ìâ´Ê£º respiratory syncytial virus;protective immunity;adenovirus recombinant;neutralization antigen;co-expression |
9Â¥2011-02-20 20:47:51
yingying1588
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 63562.9
- Ìû×Ó: 88063
- ÔÚÏß: 1554.9Сʱ
- ³æºÅ: 688753
10Â¥2011-02-20 21:58:12
11Â¥2011-02-20 22:53:18
12Â¥2013-01-25 12:12:50
13Â¥2013-01-25 13:56:16
14Â¥2013-02-17 12:41:36













»Ø¸´´ËÂ¥